| 摘要: |
| 目的:研究脾氨肽联合布地奈德治疗小儿支气管哮喘的临床疗效及对免疫功能的影响。方法:选取我院2015年2月至2017年1月收治的支气管哮喘患儿102例,其中轻度哮喘25例,中度哮喘52例,重度哮喘25例,所有患儿按照随机数字法分为对照组和观察组各51例,对照组患儿给予雾化吸入布地奈德混悬液,观察组患儿在此基础上口服脾氨肽2 mg/d 治疗,比较两组患儿的治疗总有效率、住院时间、症状消失时间、肺功能变化情况、血清免疫细胞水平以及不良反应发生率。结果:观察组治疗总有效率(94.12%)高于对照组(78.3%,P<0.05),观察组临床症状消失时间和住院时间均短于对照组(P<0.01);治疗后观察组的FVC、FEV1、FEV1/FVC、CD4+、CD8+水平均高于对照组(P<0.01),IgE水平低于对照组(P<0.01);观察组总不良反应发生率低于对照组(P<0.05)。结论:脾氨肽联合布地奈德治疗小儿支气管哮喘的临床疗效显著,可有效改善肺功能状态,提高患儿免疫力,促进患儿早日康复,且安全性较高,值得临床推广。 |
| 关键词: 脾氨肽 布地奈德 儿童 支气管哮喘 免疫功能 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.09.007 |
|
| 基金项目: |
|
| Spleen Aminopeptide Combined with Budesonide in the Treatment of Children with Bronchial Asthma and Its Effects on Serum CD4+, CD8+, IgE |
| Cai Yishu1, Chen Jian2, Chen Guochun1 |
| (1. Zhongshan Torch Development Zone Hospital, Guangdong Zhongshan 528437, China; 2. Zhongshan People's Hospital, Guangdong Zhongshan 528403, China) |
| Abstract: |
| Objective: To study the clinical efficacy of spleen aminopeptide combined with budesonide clinical efficacy in the treatment of children with bronchial asthma and its effects on immune function. Methods: One hundred and two children with bronchial asthma admitted into our hospital from Feb. 2015 to Jan. 2017 were extracted, including 25 cases of mild asthma, 52 cases of moderate asthma and 25 cases of severe asthma. All patients were divided into control group and observation group according to the random number table, with 51 cases in each group. The control group was given inhalation of budesonide, while the observation group additionally received oral spleen aminopeptide based on the control group. The total effective rate, hospitalization time, disappearance time of symptoms, changes of pulmonary function, level of serum immune cell and incidence of adverse drug reactions of two groups were compared. Results: The total effective rate of observation group (94.12%) was significantly higher than that of control group (78.43%, P<0.05); the disappearance time of symptoms and hospitalization time of observation group were significantly lower than those of control group (P<0.01). After treatment, the levels of FVC, FEV1, FEV1/FVC, CD4+ and CD8+ in observation group were significantly higher than those in control group (P<0.01); the level of IgE of observation group was significantly lower than that of control group (P<0.01).The incidence of adverse drug reactions of observation group was significantly lower than that of control group (P<0.05). Conclusion: The clinical efficacy of spleen aminopeptide combined with budesonide clinical efficacy in the treatment of children with bronchial asthma is significant, which can effectively improve the pulmonary function, increase the immune function and promote the rehabilitation of children with higher safety; it is worthy of clinical promotion. |
| Key words: spleen aminopeptide budesonide children bronchial asthma immune function |
